Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma

Treatment with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has greatly improved clinical outcomes in patients with diffuse large B-cell lymphoma (DLBCL) compared with CHOP. The mechanism of rituximab-induced cell death is poorly understood. We found that rituxi...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Zhao, Tiansuo, Ren, He, Wang, Xiuchao, Liu, Pengfei, Yan, Fan, Jiang, Wenna, Li, Yang, Li, Jing, Gribben, John G., Jia, Li, Hao, Jihui
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2015
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4695028/
https://ncbi.nlm.nih.gov/pubmed/26315113
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky